Notifications
Back

Human, Unique, Feasible & Innovative Technology

ABOUT

HUFIT

HUFIT

Technology for Human beings,

Business for Persons

HUFIT, a company that puts people first, is a company that constantly strives and researches to provide integrated solutions for infectious disease diagnosis through an extensive network of medical institutions.

VISION

COMPETITIVENESS

1.

HubCentra 84 & 448 blood culture system for sepsis diagnosis, approved by the MFDS is now entering the global market, starting from The European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in April 2024.

2.

In addition, HubCentra TB, mycobacterium tuberculosis culture system and HuPectra R-PCR MDx test kit for antibiotic-resistant bacteria are on development and 8 patents (6 registered, 2 applied) related to incubation and test exist.

3.

HUFIT’s capabilities provides clients with independent services from development, production, regulatory work, quality-control to sales and marketing by experts.

Technology for Human beings,

Business for Persons

HUFIT, a company that puts people first, is a company that constantly strives and researches to provide integrated solutions for infectious disease diagnosis through an extensive network of medical institutions.

VISION

A leading developer of

integrated solutions for

infectious disease diagnostics.

A leading developer of

integrated solutions for

infectious disease diagnostics.

Maximize customer satisfaction by

developing top quality products for

integrated infectious disease diagnostic

solutions based on customer-friendly,

feasible and innovative technologies.

Maximize customer satisfaction by

developing top quality products for

integrated infectious disease diagnostic

solutions based on customer-friendly,

feasible and innovative technologies.

COMPETITIVENESS

1.

HubCentra 84 & 448 blood culture system for sepsis diagnosis, approved by the MFDS is now entering the global market, starting from The European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in April 2024.

2.

In addition, HubCentra TB, mycobacterium tuberculosis culture system and HuPectra R-PCR MDx test kit for antibiotic-resistant bacteria are on development and 8 patents (6 registered, 2 applied) related to incubation and test exist.

3.

HUFIT’s capabilities provides clients with independent services from development, production, regulatory work, quality-control to sales and marketing by experts.



HEAD OFFICE : 1F, 308 Anmasan-ro, Chuncheon-si, Gangwon-do, Republic of Korea, 24417
FACTORY : 4-4, BIO 4, 32, Soyanggang-ro, Chuncheon-si, Gangwon-do, Republic of Korea, 24232
TEL : +82-33-258-6120    FAX : +82-504-075-2382
E-MAIL : sales@hufitdia.com

Copyright ⓒ Hufit Co.,Ltd. All rights reserved. 

HEAD OFFICE : 1F, 308 Anmasan-ro, Chuncheon-si, Gangwon-do, Republic of Korea, 24417
FACTORY : 4-2, BIO 4, 56, Soyanggang-ro, Chuncheon-si, Gangwon-do, Republic of Korea, 24232
FAX : +82-504-075-2382
E-MAIL : sales@hufitdia.com

Copyright ⓒ Hufit Co.,Ltd. All rights reserved.